progenity
announces
encouraging
preclinical
data
supporting
potential
company
oral
drug
delivery
system
targeting
colon
san
diego
globe
newswire
progenity
nasdaq
prog
biotechnology
company
established
track
record
success
developing
commercializing
molecular
testing
products
pleased
announce
positive
preliminary
preclinical
data
regarding
performance
oral
drug
delivery
system
dds
dds
capsule
uses
proprietary
autonomous
localization
technology
designed
identify
ileal
ileocecal
region
gi
tract
dds
localization
technology
based
anatomy
designed
resist
variability
physiological
conditions
like
ph
motility
bacteria
study
consisted
administration
fully
functional
dds
device
containing
mixture
acetaminophen
sulfasalazine
canine
animal
model
study
endpoints
device
function
determined
evaluation
data
recovered
capsules
pharmacokinetic
pk
results
acetaminophen
drug
products
delivered
using
dds
ingested
orally
acetaminophen
typically
absorbed
rapidly
along
entire
length
gi
tract
sulfasalazine
prodrug
metabolized
intestinal
bacteria
resulting
release
sulfapyridine
mainly
large
intestine
bacterial
concentration
elevated
progenity
pleased
report
devices
met
study
endpoints
pk
results
suggest
drug
released
large
intestine
addition
adverse
events
observed
ulcerative
colitis
poorly
managed
current
therapeutics
part
due
inability
get
sufficient
drug
concentrations
site
disease
without
side
effects
believe
dds
platform
potential
significantly
improve
patient
outcomes
producing
high
drug
concentrations
locally
site
disease
improve
efficacy
limiting
systemic
exposure
ensure
safety
said
william
sandborn
md
chief
division
gastroenterology
director
inflammatory
bowel
disease
center
university
california
san
diego
progenity
two
lead
candidates
utilizing
dds
technology
formulation
adalimumab
liquid
formulation
tofacitinib
development
treatment
ulcerative
colitis
company
previously
observed
intracecal
catheter
preclinical
colitis
models
designed
mimic
localized
delivery
dds
local
delivery
drug
product
reduction
systemic
exposure
compared
injection
exciting
data
provide
evidence
dds
platform
performed
intended
accurately
targeted
colon
technology
also
designed
allow
delivery
different
formulations
enabling
evaluation
formulations
designed
improve
stability
colonic
coverage
tissue
uptake
expect
evaluate
function
dds
normal
healthy
human
volunteers
first
quarter
said
harry
stylli
phd
ceo
chairman
board
progenity
progenity
progenity
biotechnology
company
established
track
record
success
developing
commercializing
molecular
testing
products
well
innovating
field
precision
medicine
progenity
provides
vitro
molecular
tests
designed
improve
lives
providing
actionable
information
helps
guide
patients
physicians
making
medical
decisions
key
life
stages
company
applies
approach
combining
genomics
epigenomics
proteomics
metabolomics
molecular
testing
products
development
suite
investigational
ingestible
devices
designed
provide
precise
diagnostic
sampling
drug
delivery
solutions
progenity
vision
transform
healthcare
become
precise
personal
improving
diagnoses
disease
improving
patient
outcomes
localized
treatment
targeted
therapies
information
progenity
helping
clinicians
patients
prepare
life
please
visit
forward
looking
statements
press
release
contains
statements
within
meaning
federal
securities
laws
statements
subject
substantial
risks
uncertainties
based
estimates
assumptions
statements
statements
historical
facts
included
press
release
including
statements
concerning
progress
research
development
efforts
expectations
regarding
timing
future
clinical
trials
potential
impact
patient
outcomes
statements
cases
identify
statements
terms
may
might
objective
intend
could
would
expect
believe
design
estimate
predict
potential
plan
negative
terms
similar
expressions
intended
identify
statements
statements
involve
known
unknown
risks
uncertainties
factors
could
cause
company
actual
results
differ
materially
statements
expressed
implied
press
release
risks
uncertainties
factors
include
among
others
ongoing
pandemic
associated
orders
ability
innovate
field
precision
medicine
size
growth
potential
markets
products
ability
serve
markets
rate
degree
market
acceptance
clinical
utility
products
coverage
rates
reimbursement
products
performance
third
parties
connection
commercialization
development
products
regulatory
developments
united
states
foreign
countries
ability
obtain
maintain
regulatory
approval
clearance
products
expected
timelines
ability
improve
enhance
products
plans
research
develop
commercialize
new
products
development
regulatory
approval
efficacy
commercialization
competing
products
expectations
regarding
ability
obtain
maintain
intellectual
property
protection
products
well
ability
operate
business
without
infringing
intellectual
property
rights
others
described
risk
factors
management
discussion
analysis
financial
condition
results
operations
progenity
quarterly
report
form
quarter
ended
june
filed
securities
exchange
commission
sec
subsequent
documents
file
sec
progenity
claims
protection
safe
harbor
contained
private
securities
litigation
reform
act
statements
progenity
expressly
disclaims
obligation
update
alter
statements
whether
result
new
information
future
events
otherwise
except
required
law
final
settlement
agreements
approved
signed
states
assurance
amount
accrued
sufficient
cover
progenity
obligations
relating
matter
progenity
obligations
could
also
increase
potentially
materially
depending
number
factors
including
whether
agreement
monetary
terms
states
finalized
whether
individual
state
states
opt
settlement
prior
approval
order
pursue
separate
action
resolution
terms
final
approved
agreements
parties
settlement
additional
information
please
see
note
commitments
contingencies
progenity
audited
financial
statements
year
ended
december
registration
statement
well
risk
risks
related
commercial
partners
act
manner
violates
healthcare
laws
otherwise
engage
misconduct
could
face
substantial
penalties
business
operations
financial
condition
could
adversely
investor
contact
robert
uhl
managing
director
westwicke
icr
ir
media
contact
kate
cg
life
kblomlowery
